Skip to main content

Table 1 Clinicopathological data of 19 cases with ovarian PNETs

From: Ovarian primary primitive neuroectodermal tumor: a review of cases at PUMCH and in the published literature

Author

Age (Y)

Clinical manifestation

Tumor size

Stage

Treatment

Outcome

OS

Aguirre, 1982 (Aguirre and Scully 1982) [10]

14

Increased AC, dyspnea, AUB

R/20 × 15 cm, 1278 g

IIIBa

RSO + OM + appendectomy; RAD

Progression

DOD, 2 M

Aguirre, 1982 (Aguirre and Scully 1982) [10]

13

Abdominal pain and distention after RSO+ appendectomy

8 × 5 cm

IIIa

Suboptimal CRS (LSO+ pelvic mass resection); melphalan×1; (CTX + KSM) × 2

Progression

DOD, 20 M

Aguirre, 1982 (Aguirre and Scully 1982) [10]

16

Abdominal pain; family history of tumor

L/15 cm, 464 g

IA

LSO+ appendectomy; TAH + RSO 6 days later; no adjuvant therapy

Relapse, 36 M

DOD, 47 M

Aguirre, 1982 (Aguirre and Scully 1982) [10]

17

Pelvic mass

L/18 cm

IA

LSO + ROV biopsy; no adjuvant therapy

Complete remission

NED, 84 M

Kanbour-Shak, 1993 (Kanbour-Shakir et al. 1993) [11]

35

Abdominal distention and increased AC for 2 M

R/18 × 10 × 10 cm

IIIAa

Complete surgical staging (TAH + RSO + LS (history of LOV resection) + OM + PLND+PALND); BEP × 6

Complete remission

NED, 42 M

Lawlor, 1997 (Lawlor et al. 1997) [12]

13

Intermittent fever, abdominal pain and diarrhea

Ovarian tumor 1448 g, omentum tumor 1855 g

IIICa

Suboptimal CRS (partial resection) (RSO + OM); (DDP + VP16 + doxorubicin+CTX) Q4W × 4, PBPC

Complete remission

NED, 18 M

Kawauchi, 1998 (Kawauchi et al. 1998) [13]

29

Pelvic mass

L/22 × 17 × 15 cm; R/7 × 7 × 5 cm

IIICa

Optimal CRS (without any residual disease) (TAH + BSO + OM + PALN biopsy); CHEM×12

Relapse

DOD, 11 M

PUMCH case 1, 2003b

33

Backache and lower limb aching

12.0 × 8.4 cm

IV

CHEM×11; RAD×2; PEB × 2; PVB × 1; RAD× 1; palliative surgery

Progression

DOD, 24 M

Demirtas, 2004 (Demirtas et al. 2004) [14]

25

Abdominal pain and distention for 3 M

L/8 cm

IC1

Fertility-sparing complete surgical staging (LSO + OM + partial ROV + PLND+PALND); BEP × 4; VIP × 6 when recurrent

Relapse, 3 M

NED, 28 M, CS twice

Chow, 2004 (Chow et al. 2004) [15]

13

Abdominal pain and distention for 1 M

N/A

IIICa

Optimal CRS (without any residual disease) (BSO + OM + partial bladder); PEB × 2; RCRS and RAD

Progression

DOD, 17 M

Kim, 2004 (Kim et al. 2004) [16]

18

Pelvic mass

16 × 13 cm

IIIAa

Optimal CRS (without any residual disease) (RSO + Partial LOV + OM + PLN/PALN biopsy); TC × 6; RAD when recurrent; OP when intestinal obstruction; VACA

Relapse, 4 M

Died of septic shock, 10 M

PUMCH case 2, 2005b

59

Pelvic mass

N/A

IIIa

Optimal CRS (with residual tumor less than 1 cm)

N/A

N/A

Fischer, 2006 (Fischer et al. 2006) [17]

79

Abdominal distention for 4 M

6 × 4 cm

III

Optimal CRS (TAH + BSO + OM + rectum and sigmoid colon resection+ partial bladder+ peritoneum+ PALND); CHEM

Complete remission

NED, 6 M

Ateser, 2007 (Ateser et al. 2007) [18]

28

Stomach ache, nausea and vomiting at 12 weeks of gestation

25 × 30 cm

N/A

RSO; doxorubicin+CTX + VCR; (at 37 weeks of gestation) CS + Optimal CRS (without any residual disease) (TAH + LSO + OM+ metastatic lesion); altered with VACA and PEI, RAD

Progression

DOD, 13 M

Anfinan, 2009 (Anfinan et al. 2008) [19]

31

Abdominal pain and increased AC

15 × 12 × 10 cm

IIICa

Optimal CRS (without any residual disease) (TAH + BSO + OM); Altered with VID and VIA; docetaxel+DDP

Progression

DOD, 15 M

Ostwal, 2012 (Ostwal et al. 2012) [20]

28

Pelvic mass for 2 M

12 × 11 × 10 cm

N/A

LOV resection; CHEM (Altered with VIE, VAC and VCD for 2 courses); CRS when recurrent

Relapse, 18 M

DOD, 18 M

Chu, 2014 (Chu et al. 2014) [21]

16

Pelvic mass

16.5 × 9.2 cm

IC

Fertility-sparing complete surgical staging (LSO + LPLND+OM); TC × 6

Complete remission

NED,13 M

PUMCH case 3, 2014b

67

Abdominal distention for 4 M

N/A

IIIa

Optimal CRS (without any residual disease) (history of TAH + LSO) (RSO + OM + appendectomy+partial small intestine and sigmoid colon resection); without adjuvant therapy

Progression

DOD, 6 M

PUMCH case 4, 2016b

14

Abdominal distention for one week

30 cm

IIIC

Optimal CRS (without any residual disease) (RSO + LOV biopsy+ OM + appendectomy+metastasis); TC × 1

Progression

DOD, 5 M

  1. Abbreviations: AC Abdominal circumference, AUB Atypical uterine bleeding, BSO Bilateral salpingo-oophorectomy, CHEM Chemotherapy, CRS Cytoreductive surgery, CS Cesarean section, CTX cyclophosphamide, DDP cisplatin, DOD died of disease, EP + THP Etoposide, cisplatin, pirarubicin, EP + TPT etoposide, cisplatin, topotecan, EWS Ewing’s sarcoma, IFO Ifosfamide, KSM actinomycin, L Left side, LOV Left ovary, LPLND Left pelvic lymph node dissection, LS Left salpingectomy, LSO Left salpingo-oophorectomy, M Months, N/A Not available, NED No evidence of disease, OM Omentectomy, OP Operation, OS Overall survival, PAC Cisplatin, actinomycin, cyclophosphamide, PALND Paraaortic lymph node dissection, PBPC Peripheral Blood Progenitor Cell, PEB Cisplatin, etoposide, bleomycin, PEI Cisplatin, etoposide, ifosfamide, PLND Pelvic lymph node dissection, PUMCH Peking Union Medical College Hospital, PVB Cisplatin, vincristine, bleomycin, R Right side, RAD Radiotherapy, RCRS Recytoreductive surgery, ROV Right ovary, RSO Right salpingo-oophorectomy, TAH total abdominal hysterectomy, TC Paclitaxel, carboplatin, VAC Vincristine, actinomycin, cyclophosphamide, VACA Vincristine, actinomycin, cyclophosphamide, doxorubicin, VCD Vincristine, cyclophosphamide, doxorubicin, VCR Vincristine, VIA Vincristine, ifosfamide and actinomycin, VID Vincristine, ifosfamide and doxorubicin, VIE Vincristine, ifosfamide, etoposide, VIP Vincristine, ifosfamide, cisplatin, VP16 etoposide, Y years
  2. aat least this FIGO stage
  3. bThese cases are reported in this study